Jump to main contents

Providing medical services for cardio-vascular disorders through regenerative medicine

HOME

[ Business model ]

Business model

Translational Research

As a campus venture founded within a university, our key mission is to quickly discover promising ideas from academia and translate such ideas for use by the pharmaceutical and medical-equipment industries. This is what we call translational research.
Our goal is to establish a business model in collaboration with partner companies by assuming the risks associated with early stage research and incubating the seeds from research innovations in order to reduce business risk.

Collaboration

We also believe that organized collaboration with other companies that possess promising seeds and utilization of the in-company research infrastructure and knowledge should enable us to launch better products before our competitors.
Synergistic effects are generated from a vertical collaboration with universities (translational research) and a horizontal collaboration with other companies.

Establishing and Commercializing Regenerative Medicine

Regenerative medicine aims to provide a permanent cure for damaged organs with the potential of radically altering the traditional concept of medicine.
Amid an increase in the number of patients with serious cardiovascular disorders due to the aging of the population and changing dietary habits, advances in cardiac regenerative medicine is eagerly awaited by many patients and healthcare providers.
Japan is a world leader in cardiac muscle regeneration, and the development of a novel therapy can be expected from industry-university joint research.
As a venture firm founded within academia, our mission is to bridge the basic and clinical sciences to establish cardiac regenerative medicine through translational research.
Regenerative medicine is attracting more interest as a next-generation therapy with the potential to cure cardiovascular disorders. We are striving to establish a business model for the clinical application of regenerative medicine at the earliest possible date for as many patients as possible.

Competitive Advantage of Permanent Cure Medicine Independent Administrative Institution RIKEN Center for Developmental Biology, Deputy Director Foundation for Biomedical Research and Innovation, Advisor Shinichi Nishikawa

Today's medicine is roughly classified as preventative medicine to prevent diseases, symptomatic medicine to suppress the symptoms, and curative medicine with the goal of finding a permanent cure for diseases. Though symptomatic medicine is primarily used at present, preventative medicine and curative medicine will predominate in the future. However, the permanent cure for a disease involves overcoming a number of challenges. For many diseases, incurable degeneration may persist.
For example, in myocardial infarction, which Cardio, Incorporated is working on, current treatments assume the presence of an uncured infarction site, thus symptomatic medicine is inevitably required. However, myocardial cell regeneration at the site of the infarction should render symptomatic medicine unnecessary. On the other hand, the feasibility of regenerative medicine is meeting a considerable degree of skepticism. Nevertheless, the ability to freely manipulate bio-tissue has great significance for the permanent cure of diseases.
Within this context, we expect that Cardio, Incorporated will play a central role in establishing the long-term perspectives of cell therapy.

Back to main contents
Copyright (C) 2017, Cardio Inc. All rights reserved.